The FDA Approves a Landmark Cancer Drug That Uses Genetic Engineering

Multiple sclerosis: Are we close to a cure?
September 18, 2017
Hepatitis C Acute Infection
September 18, 2017
Show all

The FDA Approves a Landmark Cancer Drug That Uses Genetic Engineering

The FDA approved a new leukemia medication.

The Food and Drug Administration on Wednesday approved a new therapy to treat leukemia in kids and young adults—a decision whose importance is as much symbolic as it is practical.

Kymriah, from the Swiss pharmaceutical company Novartis, is a cancer therapy that represents several things at once: a game-changing way to treat cancer through genetic engineering, a novel paradigm for the biotech business, and the latest turn in the debate over just how astronomically expensive a life-saving therapy can be.

Kymriah is strikingly effective for young patients with acute lymphoblastic leukemia, or ALL, but it is far more involved than taking a pill or getting an infusion. It requires inserting a human-designed gene into a patient’s own T cells so they recognize and ferociously attack cancer cells. Researchers began modifying T cells for patients in the 1990s—and now the technology called CAR T-cell therapy is finally ready for prime time in treating cancer.

Read full article: The FDA Approves a Landmark Cancer Drug That Uses Genetic Engineering – The Atlantic

Read Full Article: The FDA Approves a Landmark Cancer Drug That Uses Genetic Engineering – The Atlantic

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.